Open randomised withdrawal study of long-term azithromycin in paediatric non-cystic fibrosis bronchiectasis
Year: 2025
Type: article
Abstract: Extract International guidelines currently recommend the use for at least 6 months of azithromycin for children with non-cystic fibrosis (CF) bronchiectasis in case of >1 hospitalized or ≥3 non-hospitalized respiratory exacerbations in the previous 12 months [1, 2]. Such long-term treatment halves the frequency of exacerbation [3, 4], and possibly reduces hospitalization [2]. Question is when to stop this treatment which significantly increases macrolide-resistant bacteria carriage in the upper airway [5] and whose maximal efficacy is noted between the 17th and 62th week following initiation [6].
Source: ERJ Open Research
Authors: Jean-Christophe Dubus, Eva Foinet, Rola Abou-Taam, Caroline Thumerelle, Elsa Gachelin, Elisabeth Jouve, Patricia El Boustany, Julie Mazenq, on behalf of the AZIstop study group
Institutions: Inserm, Aix-Marseille Université, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Hôpital de la Timone, Centre de Recherche en CardioVasculaire et Nutrition, Hôpital Sainte-Marguerite, Hôpital Necker-Enfants Malades, Institut Necker Enfants Malades, Hôpital Jeanne de Flandre
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
Award: G2919861504
OpenAlex ID: W4416995320